LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
BASKING RIDGE, N.J., November 13, 2024--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and ...
The tenosynovial giant cell tumor (TGCT) trial hit its primary endpoint, teeing up an option decision that could establish ...
Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
Daiichi Sankyo Company (DSKYF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...
AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application for accelerated approval in the US for datopotamab deruxtecan for the treatment of adult patients with locally ...
AstraZeneca and Daiichi Sankyo have submitted a new biologics license application (BLA) for accelerated approval for ...
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback